ADVERTISEMENT
ADVERTISEMENT

Tag: patients

Bristol Myers Squibb Announces Adjuvant Treatment with Opdivo (nivolumab) Demonstrated Statistically Significant and Clinically Meaningful Improvement in Recurrence-Free Survival (RFS) in Patients with Stage IIB/C Melanoma in the CheckMate -76K Trial

Positive results from CheckMate -76K reinforce the potential benefit of Opdivo in earlier stages of melanoma PRINCETON, N.J.--(BUSINESS WIRE)--$BMY #CheckMate--Bristol Myers Squibb (NYSE: BMY) today announced that the Phase 3 ...

Page 1 of 10 1 2 10